Integrum AB (INTEG-B) Fair Value & Analysis
Healthcare · SE · Market cap 226M SEK
Fair value as of: Jul 11, 2026
From 1 valuation models · updated 10 days ago
Fair value updated Jul 11, 2026, revised from kr 29.74 to kr 2.00 (−93.3%) since Jun 24, 2026. Share price +1.3% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 6.96 – kr 43.10 · fair‑value band kr 1.32 – kr 2.50 · the kr 8.28 price screens above the kr 2.00 fair value. As of Jul 11, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Integrum AB (INTEG-B) currently trades at kr 8.28, while our model-based Fair Value estimate is kr 2.00, implying the stock looks roughly 75.9% overvalued today. We read business quality at 21/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Integrum AB generated revenue of 96.1M SEK at a net margin of -48.2%. Revenue declined 7.2% year over year. It earns a return on equity of -26.5%. The balance sheet holds a net cash position of 15.9M SEK. Fundamentals as of Jul 11, 2026
Our scenario range runs from kr 1.32 (bear case) to kr 2.50 (bull case); at kr 8.28, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -76%, INTEG-B screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 11, 2026. TTM = trailing twelve months.
About the company
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. It also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. It sells its implant systems to hospitals, clinics, and orthopedists worldwide. The company was incorporated in 1990 and is headquartered in Mölndal, Sweden.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Integrum AB reported revenue of kr 91.4M in FY2025 versus kr 55.7M in FY2021, a compound +13.2%/yr. Reported net income was −kr 46.3M in FY2025.
Is INTEG-B fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $90.53 | $79.67 | -12% |
| Stryker Corporation SYK | $310.00 | $186.28 | -40% |
| Medtronic plc MDTC34 | R$211.05 | R$29.52 | -86% |
| Boston Scientific Corporation B1SX34 | R$247.01 | R$234.82 | -5% |
| Edwards Lifesciences Corporation EWL | €74.64 | €31.98 | -57% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| DexCom, Inc DXCM | $74.77 | $53.93 | -28% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥141.85 | ¥147.63 | +4% |
| Koninklijke Philips N.V PHG | $26.61 | $12.54 | -53% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Integrum AB (INTEG-B) undervalued?
What is the fair value of INTEG-B?
What is the quality score of INTEG-B?
What is the revenue of Integrum AB (INTEG-B)?
What is the net profit margin of INTEG-B?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Integrum AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.